Current Cancer Drug Targets

Current Cancer Drug Targets

当前的抗癌药物靶点

  • 4区 中科院分区
  • Q3 JCR分区

期刊简介

《Current Cancer Drug Targets》是由Bentham Science Publishers B.V.出版社于2001年创办的英文国际期刊(ISSN: 1568-0096,E-ISSN: 1873-5576),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为医学-肿瘤学。作为SCIE收录期刊(JCR分区 Q3,中科院 4区),本刊采用OA未开放获取模式(OA占比0%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比55.71%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在70篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Current Cancer Drug Targets审稿周期约为 约1月 。该刊近年未被列入国际预警名单,年发文量约70篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 70 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学
4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学
4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 201 / 322

37.7%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 225 / 322

30.28%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:5.4 SJR:0.65 SNIP:0.549
学科类别 分区 排名 百分位
大类:Medicine 小类:Oncology Q2 148 / 404

63%

大类:Medicine 小类:Pharmacology Q2 140 / 313

55%

大类:Medicine 小类:Drug Discovery Q2 76 / 157

51%

大类:Medicine 小类:Cancer Research Q3 122 / 230

47%

期刊发文

  • Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives

    Author: Zhang, Yan; Li, Yafei; Fu, Qiuxia; Han, Zhiqiang; Wang, Daijie; Shinge, Shafiu A. Umar; Muluh, Tobias Achu; Lu, Xiaohong

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 4, pp. 251-264. DOI: 10.2174/1568009623666221020104603

  • Phosphoserine Aminotransferase 1: A Metabolic Enzyme Target of Cancers

    Author: Yang, Xue; Li, Chaojie; Chen, Yuping

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 3, pp. 171-186. DOI: 10.2174/1568009622666220829105300

  • Combinatorial Application of Papain and CD66B for Isolating Glioma-Associated Neutrophils

    Author: Xu, Xing; Yang, Yongchang; Liu, Yancheng; Ge, Xianglian; Yi, Tailong; Xie, Yang; Ning, Chunlan; Shen, Shengfu; Sun, Zengfeng; Zhang, Zhen; Zhai, Qiongli; Wang, Xiaoguang; Meng, Xianghui; Dong, Jun; Huang, Qiang; Yang, Xuejun; Li, Wenliang; Jin, Xun

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 5, pp. 400-411. DOI: 10.2174/1568009623666221027101637

  • Polyphyllin VII as a Potential Drug for Targeting Stemness in Hepatocellular Cancer via STAT3 Signaling

    Author: Xu, Liuhang; Chen, Ziqi; Wang, Yangbin; Li, Yulin; Wang, Zhongyu; Li, Fangzhou; Xi, Xueyan

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 4, pp. 325-331. DOI: 10.2174/1568009623666221024103834

  • HIF-1 alpha/Malat1/miR-141 Axis Activates Autophagy to Increase Proliferation, Migration, and Invasion in Triple-negative Breast Cancer

    Author: Xu, Fangyuan; Hu, Yue; Gao, Jie; Wang, Jianxiong; Xie, Yujie; Sun, Fuhua; Wang, Li; Miyamoto, Akira; Xia, Ou; Zhang, Chi

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 5, pp. 363-378. DOI: 10.2174/1568009623666221228104833

  • Present and Future Prospects of the Anti-cancer Activities of Saikosaponins

    Author: Xiao, Li-Xia; Zhou, Hui-Nian; Jiao, Zuo-Yi

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 1, pp. 2-14. DOI: 10.2174/1568009622666220806121008

  • Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis

    Author: Wang, Wei; Yuan, Dongbo; Jiang, Kehua; Li, Ruidong; Qu, Han; Jiang, Fu-Neng; Zhong, Wei-De; Sun, Fa; Jia, Zhenyu; Zhu, Jianguo

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 1, pp. 71-86. DOI: 10.2174/1568009622666220615154137

  • Geiparvarin Inhibits the Progression of Osteosarcoma by Down-regulating COX2 Expression

    Author: Wang, Bin; Du, Jia; Zhang, Zhiming; Huang, Ping; Chen, Shu; Zou, Hua

    Journal: CURRENT CANCER DRUG TARGETS. 2023; Vol. 23, Issue 5, pp. 379-387. DOI: 10.2174/1568009623666221208113432